InvestorsHub Logo
Followers 883
Posts 304355
Boards Moderated 5
Alias Born 06/09/2006

Re: None

Tuesday, 07/22/2014 11:06:03 AM

Tuesday, July 22, 2014 11:06:03 AM

Post# of 2338739
GNSZ On July 12th Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in HCC patients, presented the HCC clinical trial update for G-202, in Taipei, Taiwan.

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.